CONCLUSIONS: The new liposomal doxorubicin formulation TLD-1 showed a favourable safety profile and antitumor activity, particularly in breast cancer. RP2D was defined at 40 mg/m² administered every 3 weeks. (NCT03387917)....
Read more
Published on: 2024-02-20
Source:
Sessa Cristiana
CONCLUSION: Retinal vascular alterations were not reversible 12 months after COVID-19 and were linked to inflammation and renal dysfunction during hospitalization as well as to aortic stiffness measured during follow-up....
Read more
Published on: 2024-02-12
Source:
Sessa Cristiana